Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals insider filings show equity awards to Chief Financial Officer David Kirske. The Form 4 reports 193,254 restricted stock units granted on 08/14/2025 and two stock option grants recorded on 08/12/2025 and 08/14/2025 covering 1,073,249 and 352,800 underlying shares respectively. The options have exercise prices of $1.42 and $3.14 with expiration dates of 08/12/2035 and 08/14/2035. Vesting schedules are described: RSUs vest one-third on 02/12/2026 then quarterly over 12 months subject to continued service and shareholder approval; options vest 50% on 02/12/2026 then monthly over 12 months with certain performance-based immediate vesting for half if milestones are met before 02/12/2026.
X4 Pharmaceuticals, Inc. (XFOR) Form 3 reports that John Volpone, listed as President and a Director, filed an initial Section 16 statement for the 08/12/2025 event. The filing states no securities are beneficially owned by the reporting person at the time of the statement. The form was signed by an attorney-in-fact on 08/14/2025 and includes an Exhibit 24 power of attorney.
OrbiMed Advisors LLC filed an amended Schedule 13G reporting beneficial ownership of 134,947 warrants of X4 Pharmaceuticals, Inc., representing 1.7% of the company’s common stock on a fully diluted basis. The filing states the warrants confer shared voting and dispositive power over 134,947 warrants and that OrbiMed holds these warrants on behalf of other persons. OrbiMed’s investment and voting authority is exercised through a management committee of three named members, each disclaiming beneficial ownership. The filing affirms the holdings were not acquired to influence control of the issuer.
Bain Capital Life Sciences entities disclosed a purchase that results in collective beneficial ownership of 9.99% of X4 Pharmaceuticals (XFOR). The group participated in an August 2025 financing that issued 11,040,776 shares and 31,234,731 pre-funded warrants; BCLS II Investco purchased a pre-funded warrant exercisable for 7,047,216 shares for $9,999,999.50. The financing price was $1.42 per share and pre-funded warrants priced at $1.419 each. Concurrent with the financing, X4's board approved the termination of its CEO and CFO and appointed an Executive Chairman, a new CFO and a new President. Reporting Persons hold various shares, warrants and pre-funded warrants subject to exercise blockers that prevent exercises that would cause collective ownership to exceed 9.99% (and 4.99% for Class C Warrants). The filing references registration rights and provides warrant exercise prices and expiration dates.
X4 Pharmaceuticals completed two related private placements that raised aggregate gross proceeds of $85,000,000. The company sold common stock and pre-funded warrants, including a separate sale of pre-funded warrants to purchase up to 17,618,041 shares for approximately $25,000,000. The earlier placement raised $60 million. The purchase price per pre-funded warrant in the second placement was $1.419, and the warrants carry an exercise price of $0.001 per share, are exercisable at any time and do not expire.
The financings closed on August 13, 2025, and X4 reported that on a fully-diluted basis shares outstanding will be approximately 87.2 million. The securities were sold in private transactions under exemptions from registration (Regulation D) and the company agreed to file a registration statement to register the resale of the issued shares and shares underlying the pre-funded warrants. Copies of the agreements and a press release are filed as exhibits.
X4 Pharmaceuticals, Inc. (XFOR) entered into a Securities Purchase Agreement to sell an aggregate of 11,040,776 shares of common stock at $1.42 per share and, for certain investors in lieu of shares, pre-funded warrants to purchase 31,234,731 shares at $1.419 each, with expected aggregate gross proceeds of approximately $60 million before fees. The pre-funded warrants include customary beneficial ownership limitations and are exercisable until fully exercised. The Company agreed to file a registration statement covering the resale of the securities promptly after closing and agreed to customary indemnities and liquidated damages (1% of the invested amount per 30-day period) if registration milestones are unmet.
The filing also discloses executive leadership turnover and new appointments. The CEO and CFO resigned effective at the announced Effective Time; the Board appointed Adam R. Craig, M.D., Ph.D. as Executive Chairman and principal executive officer, John Volpone as President and David H. Kirske as Chief Financial Officer. Each incoming executive has an employment agreement with stated base salaries, target bonuses and sizeable time- and performance-based equity awards. The Board adopted an amendment increasing inducement-plan authorized shares to 11,775,643.
X4 Pharmaceuticals reported modest product sales and a significant upfront license payment but remains under material financial strain. Total revenue was $1.97 million for the quarter (product revenue $1.74 million) and $30.78 million for the six months driven by a €28.5 million upfront and €0.5 million regulatory milestone from the Norgine license, of which $27.6 million was recognized as license revenue. The company recorded a net loss of $25.7 million for the quarter and $25.5 million year-to-date. Cash, cash equivalents and short-term marketable securities totaled about $63.0 million and total assets were $105.2 million.
Management completed a 1-for-30 reverse stock split and executed a purchase agreement with Lincoln Park for up to $40.0 million (240,000 shares sold for $0.5 million through June 30, 2025). Long-term debt outstanding was $75.0 million with $76.4 million of principal and end-of-term payments due July 1, 2027. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern due to expected covenant breaches under the Hercules loan agreement and the need to raise additional capital.
X4 Pharmaceuticals, Inc. (XFOR) entered into a $40 million equity purchase agreement with Lincoln Park Capital Fund, LLC on 23 June 2025. The two-year facility allows X4 to sell newly issued common shares to Lincoln Park at the Company’s discretion.
Key mechanics
- Up to 30,000 shares per Regular Purchase, expandable to 60,000 shares when the share price is ≥ $5.00, subject to a $500,000 per-purchase cap.
- Purchase price set at 97 % of the lower of (i) the lowest trade on the purchase date or (ii) the average of the three lowest closes in the prior 10 trading days.
- Optional Accelerated and Additional Accelerated Purchases (up to 300 %/30 % of volume) follow the same 97 % pricing formula.
- Beneficial ownership cap: 4.99 % (option to lift to 9.99 % after 61 days); Exchange cap: 19.99 % of outstanding shares (≈ 1.44 million, incl. 137,099 commitment shares) unless shareholder approval or average sales price ≥ $2.67.
- X4 issued 137,099 commitment shares to Lincoln Park as a fee; no cash received for these shares.
Strategic and financial considerations
- Facility is non-exclusive; X4 may raise capital elsewhere (other than similar equity-line structures for a limited period).
- Lincoln Park is prohibited from short selling or hedging X4 stock.
- Use of proceeds: working capital and general corporate purposes.
- Company may terminate the agreement at any time without cost.
The shares are registered under the Company’s effective shelf registration (Form S-3 No. 333-273961). Copies of the Purchase Agreement, Registration Rights Agreement, and related legal opinion are filed as Exhibits 10.1, 10.2 and 5.1, respectively.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) has entered into a Purchase Agreement dated June 23, 2025 with Lincoln Park Capital Fund, LLC that allows the company to issue and sell up to US$40 million of common stock ("Purchase Shares") from time to time. In addition, 137,099 commitment shares will be issued to Lincoln Park within one business day as consideration for the agreement.
Lincoln Park will act as an underwriter under Section 2(a)(11) of the Securities Act and may resell both the Purchase Shares and the Commitment Shares; X4 will not receive any proceeds from these resales. The purchase price for each draw will be calculated using formulas set forth in the Purchase Agreement. X4 will bear issuance costs, including legal and accounting fees, but no selling commissions.
The prospectus supplement is filed under Rule 424(b)(5) on the company’s existing shelf registration statement (File No. 333-273961). X4 is classified as a smaller reporting company. The company’s stock closed at $2.67 on June 20, 2025.
Business update: X4 is commercialising XOLREMDI (mavorixafor) after FDA approval on April 29, 2024 for WHIM syndrome. U.S. launch activities include third-party logistics and specialty‐pharmacy arrangements. A Marketing Authorisation Application was validated by the EMA in January 2025, and exclusive regional distribution agreements have been signed with Norgine Pharma UK (EEA, UK, Australia, New Zealand) and Taiba Middle East Fz LLC (select MENA countries). Positive Phase 2 data in chronic neutropenia support the ongoing global Phase 3 “4WARD” study, targeted to complete enrolment in 2H-2025.
Investors should review the Risk Factors beginning on page S-8; the company describes the investment as involving a high degree of risk, particularly around dilution, market volatility and clinical execution.